BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 5, 2025
Product Development

A week of endpoint misses and trial halts: BioCentury’s Clinical Report

Bright spot was a slight rise in Protagonist shares on polycythemia vera results
BioCentury | Feb 6, 2024
Deals

Deals roundup: Novo boosts obesity manufacturing with Catalent buy

BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5
BioCentury | Nov 3, 2022
Management Tracks

Fantaccini becomes head of medical affairs, CSO at Novartis

Plus Maraganore named chair at GNS, and updates from Cardior, Protagonist and Tyra
BioCentury | Apr 15, 2022
Regulation

Protagonist’s Patel says rusfertide on track even as FDA move rattles investors

Agency reassessing breakthrough designation for polycythemia vera after adverse events
BioCentury | Apr 13, 2022
Deals

On heels of catalyst, Sierra picks GSK’s $1.9B takeout over ex-U.S. partnership

After signaling that an ex-U.S. deal was in the works, Sierra chose the M&A route, giving GSK global rights to a late-stage myelofibrosis candidate
BioCentury | Mar 28, 2022
Management Tracks

Asif Ali to join Protagonist as CFO

Plus new CMO at Avenge Bio, new CEO at 
BioCentury | Oct 12, 2021
Product Development

Oct. 11 Quick Takes: Supernus diversifies CNS portfolio with Adamas acquisition

Plus: Idorsia’s miss, Evotec, Protagonist, Enzyvant and Chance
BioCentury | Sep 18, 2021
Deals

Sept. 17 Quick Takes: Clinical hold sinks Protagonist shares

Biocon partners with Serum Institute, plus Santé’s $260M fund, IASO Bio’s $108M series C, Everest in $12M renal deal and more
BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

Keros will look to fund ongoing clinical work via a listing that builds on this month’s series C round
Items per page:
1 - 10 of 67